Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.89%
0%
-7.89%
6 Months
-23.91%
0%
-23.91%
1 Year
-33.33%
0%
-33.33%
2 Years
-10.22%
0%
-10.22%
3 Years
-10.22%
0%
-10.22%
4 Years
-40.38%
0%
-40.38%
5 Years
-40.38%
0%
-40.38%
ZYUS Life Sciences Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.16%
EBIT Growth (5y)
-268.72%
EBIT to Interest (avg)
-3.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.50
Sales to Capital Employed (avg)
0.09
Tax Ratio
15.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.08%
ROCE (avg)
0
ROE (avg)
1.57%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.13
EV to EBIT
-3.40
EV to EBITDA
-4.21
EV to Capital Employed
50.74
EV to Sales
50.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1492.80%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.08%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-3.20
-2.60
-23.08%
Interest
0.50
0.50
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.40
-4.00
-10.00%
Operating Profit Margin (Excl OI)
-32,541.70%
-28,956.10%
-358.56%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -10.00% vs 81.57% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.50
0.40
25.00%
Operating Profit (PBDIT) excl Other Income
-12.30
-15.90
22.64%
Interest
1.10
3.80
-71.05%
Exceptional Items
-19.20
-24.70
22.27%
Consolidate Net Profit
-33.80
-42.60
20.66%
Operating Profit Margin (Excl OI)
-31,804.60%
-54,190.90%
2,238.63%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.00% vs 33.33% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 20.66% vs -72.47% in Dec 2023
About ZYUS Life Sciences Corp. 
ZYUS Life Sciences Corp.
Oil
Phoenix Canada Oil Co Ltd is a Canada-based company engaged in investment management business sector. The Company maintains non-controlling equity investment positions in public companies. It also holds minority interest investments in several mature gas fields in Western Canada. The Company's objectives when managing capital are to maintain its ability to continue as a going concern in order to provide return for shareholders, and to ensure sufficient resources are available to meet daily operating requirements. The Company considers the items included in shareholders’ equity as capital. The Company manages its capital structure, and makes adjustments to it, in order to have funds available to support its corporate activities.






